ReviewOncogene2005
Viruses with deletions in antiapoptotic genes as potential oncolytic agents.
Review in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?Expert opinion on drug discovery · 2021Review
- Strategies and developments of immunotherapies in osteosarcoma.Oncology letters · 2016Article
- Article
- Adenoviral vectors for prodrug activation-based gene therapy for cancer.Anti-cancer agents in medicinal chemistry · 2014Review
- Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas.BioMed research international · 2013Article
- Homoharringtonine acts synergistically with SG235-TRAIL, a conditionally replicating adenovirus, in human leukemia cell lines.Acta pharmacologica Sinica · 2009Article
- Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses.Biochimica et biophysica acta · 2008Review
- A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.Gene therapy · 2007Article
- Oncolysis of pancreatic tumour cells by a gamma34.5-deleted HSV-1 does not rely upon Ras-activation, but on the PI 3-kinase pathway.Gene therapy · 2006Article
- A New Era in Oncology: Clinical Insights Into the Application of Oncolytic Viruses.Cancer control : journal of the Moffitt Cancer CenterReview
- Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children.Molecular therapy oncolyticsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Replication-selective oncolytic viruses have emerged as a new treatment platform for cancers. However, selectivity and potency need to be improved before virotherapy can become a standard treatment modality. In addition, mechanisms that can be incorporated to enable targeting a broad range of cancer types are highly desirable. Cancer cells are well known to have multiple blocks in apoptosis pathways. On the other hand, viruses have evolved to express numerous antiapoptotic genes to antagonize apoptosis induced upon infection. Viruses with deletions in antiapoptotic genes can therefore be complemented by antiapoptotic genetic changes in cancer cells for efficient replication and oncolysis. In this review, we summarize the recent development of this concept, the potential obstacles, and future directions for optimization.
Indexed as
Identifiers
16155595What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.